Account
Articles
16.06.2025
HST or STA? Navigating NICE’s Dual Pathways for ...

When bringing a new health technology to market in England, pharmaceutical and biotech companies mus...

Read more
Articles
09.06.2025
Early Advice, Long-Term Value: How HTA Engagement ...

The key to pricing success for any pharmaceutical product is effectively exhibiting the asset’...

Read more
Articles
02.06.2025
Joint Scientific Consultations: When, Why, and How...

The increasing complexity of bringing innovative therapies to market across various jurisdictions pr...

Read more
Articles
19.05.2025
Avoiding Common Pitfalls in HTA Scientific Advice:...

With the implementation of the EU HTA (Regulation (EU) 2025/117) and ongoing adaptation of methods u...

Read more
Articles
12.05.2025
Driving Internal Alignment: How Early HTA Advice U...

As the regulatory and market access landscape continues to evolve across Europe, timely and strategi...

Read more
Articles
07.05.2025
Unlocking Payer Confidence: Why Early HTA Scientif...

In the current pharmaceutical environment, obtaining regulatory approval is no longer enough to ensu...

Read more
Articles
23.04.2025
EU HTA Regulation for Medical Devices Starts in 20

The long-anticipated EU Health Technology Assessment (HTA) Regulation (Regulation (EU) 2021/2282) wa...

Read more
Articles
07.04.2025
Reforming Health Technology Assessments to Embrace...

The advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p...

Read more
Articles
17.03.2025
PICO and Mix: What the PICO exercises mean for JCA...

The population, intervention, comparator, and outcomes (PICO) element of the upcoming EU Joint Clini...

Read more
Articles
25.02.2025
How are countries implementing the EU HTA Regulati...

EU HTA Regulation goes live: A new era for HTA begins  The much-awaited implementation of the r...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.